

## VI. Literatur

**Abbas** AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. *Nature* 1996; 383:787-793.

**Akira** S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). *FASEB J* 1990; 4:2860-2867.

**Anderson** R. Manipulation of cell surface macromolecules by flaviviruses. In: Chambers TJ, Monath TP (Eds.), *The Flaviviruses: Structure, Replication and Evolution*. *Adv. Virus Res.* 2003; 59:229-274.

**Anggard** E. Nitric oxide: mediator, murderer, and medicine. *Lancet* 1994; 343:1199-1206.

**Arroyo** J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). *J. Virol.* 2001a; 75:934-942.

**Arroyo** J, Miller CA, Catalan J, Monath TP. Yellow fever vector live-virus vaccines: West Nile virus vaccine development. *Trends in Mol. Med.* 2001b; 7:350-354.

**Coffman** RL, Leberman DA, Rothman P. Mechanism and regulation of immunoglobulin isotype switching. *Adv. Immunol.* 1993; 54:229-270.

**Bae** HG. Untersuchungen über den Infektionsverlauf des Gelbfiebervirus in verschiedenen Zelllinien mittels Immunfluoreszenz, Plaque Assay und TaqMan-PCR. Diplomarbeit 1999; FU-Berlin.

**Bae** HG, Nitsche A, Teichmann A, Biel SS, Niedrig M. Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. *J Virol Methods.* 2003; 110(2):185-191.

**Bae** HG, Drosten C, Emmerich P, Colebunders R, Hantson P, Pest S, Parent M, Schmitz H, Warnat MA, Niedrig M. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. *J. Clin. Virol.* 2005; 33(4):274-280.

**Barrett** AD, Mathews JH, Miller BR, Medlen AR, Ledger TN, Roehrig JT. Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus. *J. Gen. Virol.* 1990a; 71:13-18.

**Barrett** AD, Monath TP, Cropp CB, Adkins JA, Ledger TN, Gould EA, Schlesinger JJ, Kinney RM, Trent DW. Attenuation of wild-type yellow fever virus by passage in HeLa cells. *J.Gen. Virol.* 1990b; 71:2301-2306.

**Barrett** AD. Yellow fever vaccines. *Biologicals* 1997; 25:17-25.

**Barros** VE, Thomazini JA, Figueiredo LT. Cytopathological changes induced by selected Brazilian flaviviruses in mouse macrophages. *J Microsc.* 2004; 216:5-14.

**Barwick** R, Eidex for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. *Lancet* 2004; 364:936.

**Besuschio** SC, Weissenbacher MC, Schmunis GA. Effect of neonatal thymectomy on encephalic lesions of newborn mice infected with yellow fever virus. *Medicina* 1976; 36(3):193-196.

**Bhardwaj** S, Holbrook M, Shope RE, Barrett AD, Watowich SJ. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. *J. Virol.* 2001; 75:4002– 4007.

**Biel** SS, Gelderblom HR. Diagnostic electron microscopy is still a timely and rewarding method. *J. Clin. Virol.* 1999; 13(1-2):105-119.

**Birnboim** HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res.* 1979; 7(6):1513-1523.

**Bisset** LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemoattractant protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. *AIDS.* 1997 Mar 15; 11(4):485-91.

**Boes** T, Neuhauser M. Normalization for Affymetrix GeneChips. *Methods Inf. Med.* 2005; 44(3):414-417.

**Breslauer** KJ, Frank R, Blocker H, Marky LA. Predicting DNA duplex stability from the base sequence. *Proc. Natl. Acad. Sci USA* 1986; 83(11):3746-3750.

**Brinton** MA. The molecular biology of West Nile Virus: a new invader of the western hemisphere. *Annu. Rev. Microbiol.* 2002; 56:371-402.

**Burke** DS, Monath TP. Flaviviruses. In: Fields BN, Knipe DM, Howley PM, Griffin DE (Eds.), *Fields Virology* 2001:1043-1125. Lippincott Williams and Wilkins, Philadelphia.

**Bustin** SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J. Mol. Endocrinol.* 2000; 25(2):169-93.

**Casadaban** MJ, Cohen SN. Analysis of gene control signals by DNA fusion and cloning in *Escherichia coli*. *J. Mol. Biol.* 1980; 138(2):179-207.

**Centers for Disease Control and Prevention.** Health information for international travel 2000-2002. Atlanta: U.S. Department of Health and Human Services; 1999.

**Centers for Disease Control and Prevention.** Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. *MMWR Morb. Mortal. Wkly. Rep.* 2001; 50:643-645.

**Centers for Disease Control and Prevention.** Fatal yellow fever in a traveler returning from Amazonas, Brazil. *MMWR Morb Mortal Wkly Rep* 2002; 51:324-325.

**Cetron** MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, Weld LH, Chen R, Clover RD, Deseda-Tous J, Marchessault V, Offit PA, Monath TP. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. *MMWR Recomm Rep.* 2002; 51:1-11.

**Chambers** TJ, Grakoui A, Rice CM. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. *J. Virol.* 1991; 65:6042-6050.

**Chang** GJ, Trent DW, Vorndam AV, Vergne E, Kinney RM, Mitchell CJ. An integrated target sequence and signal amplification assay, reverse transcriptase-PCR-enzyme-linked immunosorbent assay, to detect and characterize flaviviruses. *J. Clin. Microbiol.* 1994; 32:477-483.

**Chen** Z, Ruffner DE. Amplification of closed circular DNA in vitro. *Nucleic Acids Res.* 1998; 26:1126-1127.

**Chirgwin** JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry.* 1979; 18(24):5294-5299.

**Chu** PW, Westaway EG. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. *Virol.* 1985; 140:68-79.

**Clark** JM. Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases. *Nucleic Acids Res.* 1988; 16(20):9677-9686.

**Co** MD, Terajima M, Cruz J, Ennis FA, Rothman AL. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. *Virology* 2002; 293(1):151-163.

**Colebunders** R, Mariage JL, Coche JC, Pirenne B, Kempinaire S, Hantson P, Van Gompel A, Niedrig M, Van Esbroeck M, Bailey R, Drosten C, Schmitz H. A Belgian traveler who acquired yellow fever in the Gambia. *Clin Infect Dis.* 2002 Nov 15; 35(10):e113-116.

**Collins** PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. *J.Exp.Med.* 1995; 182:1169-1174.

**Coons** AH, Kaplan MH. Localization of antigen in tissue cells; improvements in a method for the detection of antigen by means of fluorescent antibody. *J Exp Med.* 1950 Jan 1; 91(1):1-13.

**Corver** J, Lenches E, Smith K, Robison RA, Sando T, Strauss EG, Strauss JH. Fine mapping of a cis-acting sequence element in yellow fever virus RNA that is required for RNA replication and cyclization. *J. Virol.* 2003; 77:2265-2270.

**Crill** WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. *J. Virol.* 2001; 75, 7769–7773.

**De Brito** T, Siqueira SA, Santos RT, Nassar ES, Coimbra TL, Alves VA. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. *Pathology Res. Pract.* 1992; 188:177-181.

**De Filippis** AM, Nogueira RM, Schatzmayr HG, Tavares DS, Jabor AV, Diniz SC, Oliveira JC, Moreira E, Miagostovich MP, Costa EV, Galler R. Outbreak of jaundice and hemorrhagic fever in the Southeast of Brazil in 2001: detection and molecular characterization of yellow fever virus. *J. Med. Virol.* 2002; 68(4):620-627.

**De Madrid** AT, Porterfield JS. A simple micro-culture method for the study of group B arboviruses. *Bull. WHO* 1969; 40, 113-121.

**De Vries** TJ, Fourkour A, Punt CJ, van de Locht LT, Wobbes T, van den Bosch S, De Rooij MJ, Mensink EJ, Ruiten DJ, van Muijen GN. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. *Br. J. Cancer* 1999; 80 (5-6), 883-891.

**Deubel** V, Huerre M, Cathomas G, Drouet MT, Wuscher N, Le Guenno B, Widmer AF. Molecular detection and characterization of yellow fever virus in blood and liver specimens of a non-vaccinated fatal human case. *J. Med. Virol.* 1997; 53(3): 212-217.

**Dos Santos** CN, Post PR, Carvalho R, Ferreira II, Rice CM, Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. *Virus Res.* 1995; 35(1):35-41.

**Drosten** C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, Gunther S. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. *J. Clin. Microbiol.* 2002 Jul; 40(7):2323-2330.

**Drosten** C, Kummerer BM, Schmitz H, Gunther S. Molecular diagnostics of viral hemorrhagic fevers. *Antivir. Res.* 2003; 57:61–87.

**Dunster** LM, Wang H, Ryman KD, Miller BR, Watowich SJ, Minor PD, Barrett AD. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. *Virology* 1999; 261:309-318.

**Elshuber** S, Allison SL, Heinz FX, Mandl CW. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. *J. Gen. Virol.* 2003; 84:183-191.

**Fagbami** A, Halstead SB, Marchette N, Larsen K. Heterologous flavivirus infection-enhancing antibodies in sera of Nigerians. *Am. J. Trop. Med. Hyg.* 1988; 38:205-207.

**Felgner** PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. *Proc. Natl. Acad. Sci. USA* 1987; 84(21):7413-7417.

**Ferré** F, Marchese A, Pezzoli P, Griffin S, Buxton E, Boyer V. Quantitative PCR: an overview. In: Mullis KB, Ferre F, Gibbs RA (Eds.). *The Polymerase Chain Reaction*. 1994:pp. 67-88. Birkhäuser, Boston.

**Fields Virology**. Source: Lippincott Williams & Wilkins (LWW) Edition: 4th ed. Year: 2001; ISBN: 0-7817-1832-5.

**Finlay** CJ. The mosquito hypothetically considered as the agent of transmission of yellow fever. 1881. *Mil Med*. 2001; 166(9 Suppl):5, 6-10.

**Freestone** DS. Yellow fever vaccine. In: Plotkin SA, Mortimer EA, editors. *Vaccines*. 2<sup>nd</sup> ed. Philadelphia: W.B. Saunders; 1994. p. 741-79.

**Galler** R, Freire MS, Jabor AV, Mann GF. The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector. *Braz J Med Biol Res*. 1997; 30(2):157-68.

**Galler** R, Pugachev KV, Santos CL, Ocran SW, Jabor AV, Rodrigues SG, Marchevsky RS, Freire MS, Almeida LF, Cruz AC, Yamamura AM, Rocco IM, da Rosa ES, Souza LT, Vasconcelos PF, Guirakhoo F, Monath TP. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. *Virology* 2001; 290(2):309-319.

**Gelderblom** HR, Kocks C, L'Age-Stehr J, Reupke H. Comparative immunoelectron microscopy with monoclonal antibodies on yellow fever virus-infected cells: pre-embedding labelling versus immunocryoultramicrotomy. *J. Virol. Methods* 1985; 10:225-239.

**Gelfand** DH, Holland PM, Saiki RK, Watson RM. U.S. Patent 5 210 015, 1993; *Chem. Abstr*. 1992.

**Gerasimon** G, Lowry K. Rare case of fatal yellow fever vaccine associated viscerotropic disease. *South. Med. J*. 2005; 98:653-656.

**Glare** EM, Divjak M, Bailey MJ, Walters EH. Beta-Actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels. *Thorax* 2002; 57:765-770.

**Gollins** SW, Porterfield JS. Flavivirus infection enhancement in macrophages: An electron microscopic study of viral cellular entry. *J. Gen. Virol*. 1985; 66, 1969-1982.

**Gorski** DH, Leal AD, Goydos JS. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. *J. Am. Coll. Surg*. 2003; 197:408-418.

**Goujon** C, Tohr M, Feuille V, Coulaud JP, Dupont B, San-Sonetti P. Good tolerance and efficacy of yellow fever vaccine among subjects carriers of human

immunodeficiency virus [Abstract 32]. Presented at the 4th International Conference on Travel Medicine 1995, Acapulco, Mexico, April 23–27.

**Green S**, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Rothman AL, Ennis FA. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. *J. Med. Virol.* 1999; 59(3):329-34.

**Groot H**, Riberiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. *Bull. WHO.* 1962; 27:699-707.

**Guirakhoo F**, Heinz FX, Mandl CW, Holzmann H, Kunz C. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. *J. Gen. Virol.* 1991; 72:1323-1329.

**Hacker UT**, Jelinek T, Erhardt S, Eigler A, Hartmann G, Nothdurft HD, Endres S. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. *J Infect Dis.* 1998; 177(3):774-778.

**Hahn CS**, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. *Proc. Natl. Acad. Sci. USA* 1987; 84:2019-2023.

**Halstead SB**, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. *J. Exp. Med.* 1977; 146:201-217.

**Halstead SB**. Neutralization and antibody-dependent enhancement of dengue viruses. *Adv Virus Res.* 2003; 60:421-467.

**Halstead SB**. Measuring dengue enhancing antibodies: caveats. *J Infect Dis.* 2006; 193(4):601.

**Hanley KA**, Manlucu LR, Gilmore LE, Blaney JE Jr, Hanson CT, Murphy BR, Whitehead SS. A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. *Virology.* 2003; 312(1):222-32.

**Heinz FX**, Auer G, Stiasny K, Holzmann H, Mandl C, Guirakhoo F, Kunz C. The interactions of the flavivirus envelope proteins: implications for virus entry and release. *Arch. Virol.* 1994; Suppl 9:339-348.

**Heinzel FP**, Sadick MD, Mutha SS, Locksley RM. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. *Proc. Natl. Acad. Sci. USA* 1991; 88:7011-7015.

**Holland PM**, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5' to 3' exonuclease activity of *Thermus aquaticus* DNA polymerase. *Proc. Natl. Acad. Sci. USA* 1991; 88:7276-7280.

- Holzmann** H, Heinz FX, Mandl CW, Guirakhoo F, Kunz C. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. *J Virol.* 1990; 64(10):5156-9.
- Hotchkiss** RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med* 2003; 348:138–50.
- Janeway** CA Jr, Medzhitov R. Innate immune recognition. *Annu. Rev. Immunol.* 2002; 20:197-216.
- Jankovic** D, Liu Z, Gause WC. Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. *Trends Immunol.* 2001; 22:450-457.
- Jaspert** R, Geske T, Teichmann A, Kassner YM, Kretzschmar K, L´age-Stehr J. Laboratory scale production of monoclonal antibodies in a tumbling chamber. *J. Immunol. Methods* 1995; 178, 77-87.
- Jennings** AD, Gibson A, Miller BR, Mathews JH, Mitchell CJ, Roehrig JT, Woods DJ, Taffs F, Sil BK, Whitby SN, Whitby JE, Monath TP, Minor PD, Sanders PG, Barret ADT. Analysis of a yellow fever virus isolated from a fatal case of vaccine associated human encephalitis. *J. Infect. Dis.* 1994; 169:512-518.
- Keilholz** U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K, de Vries T, Blaheta J, Voit C, Lethe B, Burchill S. Reliability of reverse transcription-polymerase chain reaction (RT-PCR) based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. *Eur. J. Cancer* 1998; 34:750-753.
- Kerr** JA. The clinical aspects and diagnosis of yellow fever. In: Strode GK (Ed.) *Yellow Fever* (1951); pp. 348-425. McGraw-Hill, New York.
- Khaiboullina** SF, Rizvanov AA, Holbrook MR, St Jeor S. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. *Virology* 2005; 342(2):167-176.
- Khromykh** AA, Westaway EG. Subgenomic replicons of the flavivirus Kunjin: construction and applications. *J. Virol.* 1997; 71:1497-1505.
- Kohler** S, Wagner U, Pierer M, Kimmig S, Oppmann B, Mowes B, Julke K, Romagnani C, Thiel A. Post-thymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults. *Eur J Immunol.* 2005; 35(6):1987-1994.
- Kohler** G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. *J. Immunol.* 2005; 174(5):2453-5.
- Khromava** AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS, The Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. *Vaccine* 2005; 23:2356-63.

- Koraka P**, Zeller H, Niedrig M, Osterhaus AD, Groen J. Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. *Microbes Infect.* 2002; 4(12):1209-1215.
- Kurane I**, Okamoto Y, Dai LC, Zeng LL, Brinton MA, Ennis FA. Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8-cytotoxic T lymphocyte clones. *J Gen Virol.* 1995; 76:2243-2249.
- Laemmli UK**. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970; 227(259):680-685.
- Liew FY**. T(H)1 and T(H)2 cells: a historical perspective. *Nat. Rev. Immunol.* 2002; 2(1):55-60.
- Lindenbach BD**, Rice CM. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. *J. Virol.* 1999; 73:4611-4621.
- Lindenbach BD**, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM (Eds.) *Fields virology* (2001); pp. 991-1041. Lippincott Williams & Wilkins, Philadelphia.
- Liprandi F**, Walder R. Replication of virulent and attenuated strains of yellow fever virus in human monocytes and macrophage-like cells (U937). *Arch. Virol.* 1983; 76(1):51-61.
- Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; 25(4):402-408.
- Lobigs M**, Dalgarno L, Schlesinger JJ, Weir RC. Location of neutralization determinant in the E protein of Yellow Fever Virus (17D vaccine strain). *Virology* 1987; 161, 474-478.
- Lu B**, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. *J. Exp. Med.* 1998; 187(4):601-8.
- Mackay IM**, Arden KE, Nitsche A. Real-time PCR in virology. *Nucleic Acids Res.* 2002; 30 (6): 1292-1305.
- Mandl CW**, Guirakhoo F, Holzmann H, Heinz FX, Kunz C. Antigenic structure of the flavivirus envelope E protein at the molecular level using tick-borne encephalitis virus as a model. *J. Virol.* 1989; 63:564-571.
- Mandl CW**, Allison S, Holzmann H, Meixner T, Heinz FX. Attenuation of tick-borne encephalitis virus by structure-based site specific mutagenesis of a putative flavivirus receptorbinding site. *J. Virol.* 2000; 74, 9601– 9609.
- Marianneau P**, Steffan AM, Royer C, Drouet MT, Kirn A, Deubel V. Differing infection patterns of dengue and yellow fever viruses in a human hepatoma cell line. *J Infect Dis.* 1998; 178(5):1270-1278.



**Martin** M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, Shieh W, Zaki SR, Al-Sanouri I, Cutrona AF, Ray G, Weld LH, Cetron MS. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. *Lancet*. 2001; 358(9276):98-104.

**Martins** RM, Galler R, Freire MS, Camacho LA, Maia MD, Homma A. Yellow fever vaccination: Some thoughts on how much is enough. *Vaccine* 2006 Jan 18 [Epub ahead of print].

**Maruo** N, Morita I, Shirao M, Murata S. IL-6 increases endothelial permeability in-vitro. *Endocrinology* 1992; 131:710-714

**Massad** E, Coutinho FA, Burattini MN, Lopez LF, Struchiner CJ. Yellow fever vaccination: how much is enough? *Vaccine* 2005; 23:3908-14.

**Medzhitov** R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. *Curr. Opin. Immunol.* 1997; 9:4-9.

**Mill** J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3' UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. *Am. J. Med. Genet.* 2002; 114, 975–979.

**Modis** Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. *Proc. Natl. Acad. Sci. USA* 2003; 100:6986-6991.

**Monath** TP, Kinney RM, Schlesinger JJ, Brandriss MW, Bres P. Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide. *J Gen Virol* 1983; 64:627–37.

**Monath** TP, Nystrom RR. Detection of yellow fever virus in serum by enzyme immunoassay. *Am. J. Trop. Med. Hyg.* 1984; 33,151-157.

**Monath** TP. Yellow Fever. 139-232. In: Monath TP (Ed.). *The Arboviruses: Epidemiology and Ecology*. 1989; 139-231; CRC Press, Boca Raton, Florida.

**Monath** TP and Heinz FX. Flaviviruses. In: Fields BN, Knipe DM, Howley PM (Eds.) *Fields Virology* 1996, 3,961–1034. Lippincott-Raven: Philadelphia.

**Monath** TP. Yellow fever. In: Plotkin SA, Orenstein WA, editors. *Vaccines*. 3<sup>rd</sup> ed. Philadelphia: W.B. Saunders Company; 1999. p. 815-79.

**Monath** TP. Yellow fever: an update. *Lancet Infect Dis.* 2001; 1(1):11-20.

**Monath** TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. *Am J. Trop. Med. Hyg.* 2002; 66(5):533-541.

**Monath** TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. *Clin Infect Dis.* 2002; 34(10):1369-78.

**Monath** TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. *Adv. Virus Res.* 2003; Vol 60, 343-395.

**Mosmann** TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J. Immunol.* 1986; 136:2348-2357.

**Mosmann** TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu. Rev. Immunol.* 1989; 7:145-173.

**Moss** WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. *Bull. WHO* 2003; 81(1):61-70.

**Mutebi** JP, Wang H, Li L, Bryant JE, Barrett AD. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. *J. Virol.* 2001; 75(15):6999-7008.

**Mutebi** JP, Barrett AD. The epidemiology of yellow fever in Africa. *Microbes Infect.* 2002; 4(14):1459-1468.

**Muylaert** IR, Chambers TJ, Galler R, Rice CM. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. *Virology* 1996; 222(1):159-168.

**Niedrig** M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. *Trop. Med. Int. Health.* 1999; 4(12):867-871.

**Niesters** HG. Quantitation of viral load using real-time amplification techniques. *Methods* 2001; 25(4):419-429.

**Paul** WE. Interleukin-4: a prototypic immunoregulatory lymphokine. *Blood* 1991; 77:1859-1870.

**Pawlotsky** JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. *Hepatology* 2000; 32(3):654-659.

**Peccoud** J, Jacob C. Theoretical uncertainty of measurements using quantitative polymerase chain reaction. *Biophys. J.* 1996; 71,101-108.

**Pfaffl** MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. *Biotechnol. Lett.* 2004, 26:509-515.

**Pinsky** MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. *Chest* 1993; 103:565-575.

- Poland** JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. *Bull. WHO* 1981; 59:895-900.
- Porterfield** JS. A plaque technique for the titration of Yellow Fever Virus and antisera. *Trans. R. Soc. Trop. Med. Hyg.* 1959; 53:458-466.
- Racaniello** VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. *Proc Natl. Acad. Sci. USA.* 1981; 78(8):4887-4891.
- Radonic** A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A: Guideline to reference gene selection for quantitative real-time PCR. *Biochem. Biophys. Res. Commun.* 2004, 313:856-862.
- Radonic** A, Thulke S, Bae HG, Muller MA, Siegert W, Nitsche A. Reference gene selection for quantitative real-time PCR analysis in virus infected cells: SARS corona virus, Yellow fever virus, Human Herpesvirus-6, Camelpox virus and Cytomegalovirus infections. *Viol. J.* 2005; 2:7.
- Reinhardt** B, Jaspert R, Niedrig M, Kostner C, L´age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. *J. Med. Virol.* 1998; 56:159-67.
- Rengarajan** J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. *Immunol. Today* 2000; 21(10):479-483.
- Rey** FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. *Nature* 1995; 375:291-298.
- Reynolds** ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. *J. Cell. Biol.* 1963; 17:208-212.
- Rice**, CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. *Science* 1985; 229:726-733.
- Rice** CM. Flaviviridae: the viruses and their replication. In: Fields BN, Knipe DM and Howley PM (Eds.), *Fields Virology* (1996); pp. 931-960. Lippincott-Raven: Philadelphia.
- Robertson** SE, Hull BP, Tomori O, Bele O, LeDuc JW, Esteves K. Yellow fever: a decade of reemergence. *JAMA* 1996; 276:1157-1162.
- Romagnani** S. Lymphokine production by human T cells in disease states. *Annu. Rev. Immunol.* 1994; 12:227-257.
- Ryman** KD, Xie H, Ledger TN, Campbell GA, Barrett AD. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. *Virology.* 1997 Apr 14;230(2):376-80.

- Ryman** KD, Ledger TN, Campbell GA, Watowich SJ, Barrett AD. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. *Virology*. 1998 Apr 25;244(1):59-65.
- Sadick** MD, Locksley RM, Tubbs C, Raff HV. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to *Leishmania* antigens in vitro. *J. Immunol*. 1986; 136:655-661.
- Sambrook** J, Fritsch EF, Maniatis T. *Molecular Cloning: A Laboratory Manual* (1989). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Sanger** F, Nickeln S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci*. 1977; 74:5463-5467.
- Schill** G, Arvidsson E. Application of indirect detection methods in biomedical analysis. *J. Chromatogr*. 1989; 492:299-318.
- Schlesinger** JJ, Brandriss MW, Monath TP. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition and immune precipitation of the virus envelope protein. *Virology* 1983; 125:8-17.
- Schlesinger** JJ, Brandriss MW. 17D yellow fever virus infection of P388D1 cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor. *J. Gen Virol*. 1983; 64:1255-1262.
- Seder** RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. *Annu. Rev. Immunol*. 1994; 12:635-73.
- Selvey** S, Thompson EW, Matthaei K, Lea RA, Irving MG, Griffiths LR: Beta-actin--an unsuitable internal control for RT-PCR. *Mol. Cell. Probes* 2001, 15:307-311.
- Severson** DW, Knudson DL, Soares MB, Loftus BJ *Aedes aegypti* genomics. *Insect Biochem. Mol. Biol*. 2004; 34(7):715-721
- Shenoy** AR, Visweswariah SS. Site-directed mutagenesis using a single mutagenic oligonucleotide and DpnI digestion of template DNA. *Anal. Biochem*. 2003; 319,335-336.
- Sibailly** TS, Wiktor SZ, Tsai TF, Cropp BC, Ekpini ER, Adjorlolo-Johnson G, Gnaore E, DeCock KM, Greenberg AE. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. *Pediatr. Infect. Dis. J*. 1997;16(12):1177-1179.
- Smith** LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR, Heiner C, Kent SB, Hood LE. Fluorescence detection in automated DNA sequence analysis. *Nature* 1986; 321(6071):674-649.
- Snapper** CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. *Science* 1987; 236:944-947.

- Sturzenbaum** SR, Kille P. Control genes in quantitative molecular biological techniques: the variability of invariance. *Comp. Biochem. Physiol. B. Biochem. Mol. Biol.* 2001; 130(3):281-289.
- Tanaka** M. Rapid identification of flavivirus using the polymerase chain reaction. *J. Virol. Methods.* 1993; 41(3):311-322.
- Tattevin** P, Depatureaux AG, Chapplain JM, Dupont M, Souala F, Arvieux C, Poveda JD, Michelet C. Yellow fever vaccine is safe and effective in HIV-infected patients. *AIDS* 2004; 18(5):825-827.
- Teichmann** D, Grobusch MP, Wesselmann H, Temmesfeld-Wollbruck B, Breuer T, Dietel M, Emmerich P, Schmitz H, Suttrop N. A haemorrhagic fever from the Cote d'Ivoire. *Lancet.* 1999; 354(9190):1608.
- Ter Meulen** J, Sakho M, Koulemou K, Magassouba N, Bah A, Preiser W, Daffis S, Klewitz C, Bae HG, Niedrig M, Zeller H, Heinzel-Gutenbrunner M, Koivogui L, Kaufmann A. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. *J Infect Dis.* 2004; 190(10):1821-7.
- Theiler** M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. *J. Exp. Med.* 1937; 65:787-800.
- Tomori** O. Yellow fever: the recurring plague. *Crit. Rev. Clin. Lab. Sci.* 2004; 14(4):391-427.
- Trent** DW, Grant JA, Vorndam AW, Monath TP. Genetic heterogeneity among St. Louis encephalitis virus isolates of different geographic origin. *Virology* 1981; 114:319-332.
- Troillet** N, Laurencet F. Effects of yellow fever vaccination. *Lancet* 2001; 358(9296):1908-1909.
- Vainio** J, Cutts F. Yellow fever. Geneva, WHO; Global Programme for vaccines and immunization. 1998.
- Van der Most** RG, Murali-Krishna K, Ahmed R, Strauss JH. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. *J. Virol.* 2000; 74(17):8094-8101.
- Vandesompele** J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 2002; 3(7). [Epub 2002 Jun18].
- Van Kuppeveld** FJ, Melchers WJ, Willemse HF, Kissing J, Galama JM, van der Logt JT. Detection of *Mycoplasma pulmonis* in experimentally infected laboratory rats by 16S rRNA amplification. *J. Clin. Microbiol.* 1993; 31(3):524-527.
- Vasconcelos** PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, Monath TP, Rodrigues SG, Laval C, Costa ZG, Vilela MF, Santos CL, Papaiordanou PM, Alves VA, Andrade LD, Sato HK, Rosa ES, Froguas GB, Lacava E, Almeida LM, Cruz AC, Rocco IM, Santos RT, Oliva OF; Brazilian Yellow Fever Vaccine Evaluation Group. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. *Lancet* 2001; 358(9276):91-7.

**Vasquez S**, Valdes O, Pupo M, Delgado I, Alvarez M, Pelegrino JL, Guzman MG. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. *J. Virol. Methods.* 2003; 110(2):179-184.

**Vieira WT**, Gayotto LC, de Lima CP, de Brito T. Histopathology of the human liver in yellow fever with special emphasis on the diagnostic role of the Councilman body. *Histopathology* 1983; 7(2):195-208.

**Villinger F**, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. *J. Infect. Dis.* 1999; 179 Suppl 1:S188-91.

**Vogelstein B**, Gillespie D. Preparative and analytical purification of DNA from agarose. *Proc. Natl. Acad. Sci. USA* 1979; 76(2):615-619.

**Wardlaw AJ**, Moqbel R, Kay AB. Eosinophils: biology and role in disease. *Adv. Immunol.* 1995; 60:151-266.

**Wheelock EF**, Sibley WA. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. *N Engl J Med.* 1965; 273:194-198.

**WHO**. Prevention and control of yellow fever in Africa. 1985. Geneva, World Health Organization.

**Wills-Karp M**. Immunologic basis of antigen-induced airway hyper-responsiveness. *Annu. Rev. Immunol.* 1999; 17:255-281.

**Wilson ME**. Travel-related vaccines. *Infect Dis Clin North Am.* 2001; 15(1):231-251.

**You S**, Padmanabhan R. A novel in vitro replication system for Dengue virus. Initiation of RNA synthesis at the 3'-end of exogenous viral RNA templates requires 5'- and 3'-terminal complementary sequence motifs of the viral RNA. *J. Biol. Chem.* 1999; 274:33714-33722.

**Yusof R**, Clum S, Wetzel M, Murthy HM, Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. *J. Biol. Chem.* 2000; 275:9963-9969.

**Zhong H**, Simons JW. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. *Biochem. Biophys. Res. Commun.* 1999; 259:523-526.